Literature DB >> 20816079

Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.

Nevra Ozer1, Celia A Schiffer, Turkan Haliloglu.   

Abstract

The structural fluctuations of HIV-1 protease in interaction with its substrates versus inhibitors were analyzed using the anisotropic network model. The directions of fluctuations in the most cooperative functional modes differ mainly around the dynamically key regions, i.e., the hinge axes, which appear to be more flexible in substrate complexes. The flexibility of HIV-1 protease is likely optimized for the substrates' turnover, resulting in substrate complexes being dynamic. In contrast, in an inhibitor complex, the inhibitor should bind and lock down to inactivate the active site. Protease and ligands are not independent. Substrates are also more flexible than inhibitors and have the potential to meet the dynamic distributions that are inherent in the protease. This may suggest a rationale and guidelines for designing inhibitors that can better fit the ensemble of binding sites that are dynamically accessible to the protease. Copyright 2010 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816079      PMCID: PMC2931728          DOI: 10.1016/j.bpj.2010.06.064

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  51 in total

1.  Protein flexibility and dynamics using constraint theory.

Authors:  M F Thorpe; M Lei; A J Rader; D J Jacobs; L A Kuhn
Journal:  J Mol Graph Model       Date:  2001       Impact factor: 2.518

2.  Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations.

Authors:  Nese Kurt; Walter R P Scott; Celia A Schiffer; Turkan Haliloglu
Journal:  Proteins       Date:  2003-05-15

3.  Protein flexibility prediction by an all-atom mean-field statistical theory.

Authors:  B P Pandey; Chi Zhang; Xianzhang Yuan; Jian Zi; Yaoqi Zhou
Journal:  Protein Sci       Date:  2005-07       Impact factor: 6.725

4.  Functional modes of proteins are among the most robust.

Authors:  S Nicolay; Y-H Sanejouand
Journal:  Phys Rev Lett       Date:  2006-02-24       Impact factor: 9.161

5.  A unification of the elastic network model and the Gaussian network model for optimal description of protein conformational motions and fluctuations.

Authors:  Wenjun Zheng
Journal:  Biophys J       Date:  2008-01-30       Impact factor: 4.033

6.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere.

Authors:  A Krohn; S Redshaw; J C Ritchie; B J Graves; M H Hatada
Journal:  J Med Chem       Date:  1991-11       Impact factor: 7.446

7.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.

Authors:  Z Chen; Y Li; E Chen; D L Hall; P L Darke; C Culberson; J A Shafer; L C Kuo
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

10.  X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.

Authors:  Herbert E Klei; Kevin Kish; Pin-Fang M Lin; Qi Guo; Jacques Friborg; Ronald E Rose; Yaqun Zhang; Valentina Goldfarb; David R Langley; Michael Wittekind; Steven Sheriff
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

View more
  4 in total

1.  Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs.

Authors:  N A Kuznetsov; A V Kozyr; M A Dronina; I V Smirnov; E N Kaliberda; A G Mikhailova; L D Rumsh; O S Fedorova; A G Gabibov; A V Kolesnikov
Journal:  Dokl Biochem Biophys       Date:  2011-11-19       Impact factor: 0.788

2.  Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Authors:  Jeff A O'Meara; Christopher T Lemke; Cédrickx Godbout; George Kukolj; Lisette Lagacé; Benoît Moreau; Diane Thibeault; Peter W White; Montse Llinàs-Brunet
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

3.  Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution.

Authors:  Nevra Özer; Ayşegül Özen; Celia A Schiffer; Türkan Haliloğlu
Journal:  Evol Appl       Date:  2015-01-11       Impact factor: 5.183

4.  Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease.

Authors:  Yong Wang; Tamaria G Dewdney; Zhigang Liu; Samuel J Reiter; Joseph S Brunzelle; Iulia A Kovari; Ladislau C Kovari
Journal:  Biology (Basel)       Date:  2012-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.